HighTower Advisors LLC Increases Stock Position in Grifols, S.A. (NASDAQ:GRFS)

HighTower Advisors LLC raised its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 12.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,930 shares of the biotechnology company’s stock after purchasing an additional 1,546 shares during the period. HighTower Advisors LLC’s holdings in Grifols were worth $123,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Brandes Investment Partners LP increased its holdings in shares of Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after buying an additional 1,481,924 shares during the last quarter. Armistice Capital LLC raised its position in Grifols by 18.7% during the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after purchasing an additional 1,244,000 shares during the period. Highland Peak Capital LLC bought a new stake in shares of Grifols in the 2nd quarter valued at approximately $5,991,000. Black Creek Investment Management Inc. boosted its holdings in shares of Grifols by 7.7% in the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after purchasing an additional 881,155 shares during the period. Finally, Whitebox Advisors LLC boosted its holdings in shares of Grifols by 45.6% in the 2nd quarter. Whitebox Advisors LLC now owns 2,702,390 shares of the biotechnology company’s stock worth $17,039,000 after purchasing an additional 846,940 shares during the period.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Stock Performance

Shares of NASDAQ:GRFS opened at $7.85 on Friday. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 12 month low of $5.30 and a 12 month high of $12.15. The company has a market capitalization of $5.40 billion, a price-to-earnings ratio of 8.09 and a beta of 0.43. The firm’s 50-day moving average is $8.29 and its 200 day moving average is $8.12.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.